Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y3D3
UPID:
RT16_HUMAN
Alternative names:
28S ribosomal protein S16, mitochondrial
Alternative UPACC:
Q9Y3D3; B4E032; Q96Q60
Background:
The Small ribosomal subunit protein bS16m, also known as 28S ribosomal protein S16, mitochondrial, plays a crucial role in the mitochondrial ribosome. Its primary function involves participating in the synthesis of proteins within mitochondria, essential for cellular energy production and metabolic processes.
Therapeutic significance:
Understanding the role of Small ribosomal subunit protein bS16m could open doors to potential therapeutic strategies for combating Combined oxidative phosphorylation deficiency 2, a severe mitochondrial disease leading to fatal neonatal metabolic acidosis.